The fact that new genes emerge during speciation is not unexpected, although their significance to the injury response remains largely enigmatic. Yet, for over 60 years, a tenet of modern molecular biology has held that essential genes, like those needed for tissue repair, have significant protein and/or DNA sequence homology across multiple species.[1](#wrr12422-bib-0001){ref-type="ref"} As a consequence, the contributions of human‐specific genes to the onset and progression of human disease have been largely understudied.[2](#wrr12422-bib-0002){ref-type="ref"} In contrast, the genetic mechanisms to explain the emergence of these taxonomically restricted genes are well described. They include complete and/or partial gene duplication, gene rearrangement, silencing, mutagenesis and, the endogenization of foreign DNA.[3](#wrr12422-bib-0003){ref-type="ref"}

If an increased incidence of injury can be associated with or be the result of newly acquired behaviors, then it is reasonable to presume that plasticity in the inflammatory response can contribute to the emergence of new genes. This raises the possibility that selection pressures conferred by injury, and specifically the inflammatory responses that are tied to injury, might drive the adaptation of newly emerged genes to new functions in inflammatory cells. To this end, it is noteworthy that the ancestors of homo sapiens acquired three new injury‐prone behaviors that are hallmarks of the species. First, when early hominid moved between trees and the savannah, they became erect and bipedal. Second, they learned to use tools and weapons so as to modify their environment for hunting and compete for habitation. Finally, when hominid harnessed fire and turned to cooking food, their gut microbiome was fundamentally altered. Presumably, the acquisition of these behaviors came with significant risk for trauma and burn injury: bipedal motion and tool/weapon‐making skills led to the appearance of new kinds of pressure and penetrating injuries while the use of fire, another uniquely human activity, was likely associated with accidental burn of skin and hair and smoke inhalation. Like no other species, some early human societies are even known for using injury response (scar formation) to confer reproductive advantage.

In modern humans, there are approximately 300 human‐specific genes that distinguish the human genome from that of great apes.[4](#wrr12422-bib-0004){ref-type="ref"} There are perhaps another 2,000 that differentiate primates from other species.[3](#wrr12422-bib-0003){ref-type="ref"} For the most part, however, the reasons for the retention of these genes in the human genome remain to be investigated. Neuroscientists posit that human‐specific genes were selected to regulate traits that are uniquely human: size of the human brain, cognition, memory, and consciousness. To others, their very existence has been enigmatic, their functions unknown and the reasons for their over‐representation in complex human disease,[5](#wrr12422-bib-0005){ref-type="ref"} an interesting, albeit cursory problem in translational research. We hypothesize here that the opposite may be true, and that the very existence of human‐specific genes may help explain intrinsic problems in the representation of human inflammatory disease in animal models.

In an in silico survey of candidate taxonomically restricted genes, we were struck by the number of human‐specific genes that are expressed in blood‐derived cells, most often leukocytes and lymphocytes (Table [1](#wrr12422-tbl-0001){ref-type="table-wrap"}). We also noted that the expression of these genes is often associated with the biology of injury, namely infection, inflammation, and tissue repair and regeneration. These genes include well‐known anti‐infection and human‐specific defensin genes (Table [1](#wrr12422-tbl-0001){ref-type="table-wrap"}), some of which specifically localize to human neutrophils. They also include more recently uncovered genes, like CHRFAM7A, ARHGAP11B and TBC1D3 that are either linked injury responses like the cholinergic regulation of inflammation by the α7‐nicotinic acetyl choline receptor (α7−nAChR), to growth factor‐mediated signal transduction through *rho*‐mediated signal transduction or to the regulation of microvescle exocytosis and endocytosis, respectively (Table [1](#wrr12422-tbl-0001){ref-type="table-wrap"}).

###### 

Human‐specific genes and inflammatory cells

  Gene name and/or gene family[\*](#wrr12422-note-0001){ref-type="fn"}   Gene ID (Ensembl)                                                                                                                                Known, putative and/or inferred function(s)[\*](#wrr12422-note-0001){ref-type="fn"}   Immune and injury cell expression   Reference[\*](#wrr12422-note-0001){ref-type="fn"}
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------------------------
  CHRFAM7A                                                               ENSG00000166664                                                                                                                                  Receptor antagonist                                                                   BM,WB, L, LN, T                     J Leukoc Biol. 2015; 97:247
  TBC1D3                                                                 ENSG00000274611                                                                                                                                  Endocytosis/pinocytosis                                                               BM,WB, L, LN, T                     Genomics. 2006; 88:731
  ARHGAP11B                                                              ENSG00000187951                                                                                                                                  Rho GTPase activating                                                                 WB, L,LN                            Science. 2015; 347:1465
  CCL18                                                                  ENSG00000275385                                                                                                                                  Immunoregulation                                                                      BM, WB, LN, T                       Genomics. 1999; 55:353
  CCL23 (MIP‐3)                                                          ENSG00000274736                                                                                                                                  Leukocyte chemotaxis                                                                  BM, WB, LN, T                       J Exp Med. 1997;185:1163
  NLGN4X (Neuroligin4X)                                                  ENSG00000146938                                                                                                                                  Tissue remodeling                                                                     BM, WB, LN, T                       Nat Genet. 2003; 34:27
  Interleukin 26                                                         ENSG00000111536                                                                                                                                  T cell responsiveness                                                                 BM, WB, LN, T                       J Virol. 2000;74: 3881
  IFNL1                                                                  ENSG00000182393                                                                                                                                  Antiviral host defense                                                                WB, LN                              J Biol Chem. 2004;279:32269
  ANGPTL5 (Angiopoietin‐like)                                            ENSG00000187151                                                                                                                                  Tissue regeneration                                                                   WB LN                               J Hum Genet. 2003;48:159
  Alpha Defensin (*N* = 5; DEFA1B,A3, A4, A5, A6)                        ENSG00000240247 ENSG00000239839 ENSG00000164821 ENSG00000164816 ENSG00000164822                                                                  Antimicrobial peptides                                                                BM,WB, L, LN, T                     Physiol. Gen 2004; 20: 1
  Beta Defensin (*N* = 5; DEF4B, B104A, B104B, B114, B132)               ENSG00000177257 ENSG00000176782 ENSG00000177023 ENSG00000177684 ENSG00000186458                                                                  Antimicrobial peptides                                                                BM, WB, LN, T                       Genome Biol. 2003;4:R31
  NPIP genes (*N* = 2; NPIP‐A1 and B11)                                  ENSG00000183426 ENSG00000254206                                                                                                                  Nuclear pore proteins                                                                 BM, WB, LN, T                       Nature. 2001; 413:514
  CSAG (*N* = 2; CSAG1, CSAG2)                                           ENSG00000198930 ENSG00000268902                                                                                                                  Cell growth and tumor antigen                                                         WB, LN                              Gene. 1999;229:75
  c20orf203 (Alugen)                                                     ENSG00000198547                                                                                                                                  Neurodegeneration                                                                     WB                                  PLoS Comput Biol. 2010;6:e1000734
  *SPANX genes (N = 9; SPANXB1, D, A2, C, A1, N3, N2, N5, N1)*           ENSG00000227234 ENSG00000196406 ENSG00000203926 ENSG00000198573 ENSG00000198021 ENSG00000189252 ENSG00000268988ENSG00000204363 ENSG00000203923   Nuclear proteins, spermatogenesis and cancer antigens                                 BM, WB, LN, T                       Proc Natl Acad Sci USA.2004;101:3077
  VCX genes (*N* = 3; VCX2, VCX3A, VCX3B)                                ENSG00000182583 ENSG00000177504 ENSG00000169059 ENSG00000205642                                                                                  mRNA stability reproduction                                                           WB                                  Cancer Res. 2014; 74:4694
  VCY                                                                    ENSG00000129864                                                                                                                                  Nuclear protein                                                                       BM, WB, LN, T                       Mol Reprod Dev. 2008; 75:219
  OPN genes OPN1MW                                                       ENSG00000268221 ENTREZ: 100534624                                                                                                                Locus control for opsin trichromatic vision                                           BM, WB, LN, T                       Trends Ecol Evol 2003; 18:198
  VN1R genes (VN1R3)                                                     ENSG00000180663 (mouse, no rat)                                                                                                                  Olfactory chemosensory                                                                BM, WB, LN, T                       Genome Res. 2010;20:10
  STRA6                                                                  ENSG00000137868                                                                                                                                  light adaptation                                                                      BM, WB, LN, T                       PLoS One. 2014;9:e108388
  NBPF                                                                   ENSG00000162825                                                                                                                                  Development                                                                           BM, WB, LN, T                       Mol Biol Evol. 2005; 22:2265
  CT45 genes (*N* = 4; CT45A1, A2, A3, A4)                               ENSG00000268940 ENSG00000271449 ENSG00000269096 ENSG00000271449                                                                                  B cell lymphoma                                                                       BL                                  Proc Natl Acad Sci USA. 2005;102:7940

\*See [www.gencards.org](http://www.gencards.org) for details on genes, gene ontogeny, orthologs, paralogs, inferred and known functions and relative tissue expression.

BM, bone marrow; BL, B cell lymphoma; WB, whole blood; LN, lymph node; T, thymus; LL, leukocytes and lymphocytes as determined by microarray.

Numerous investigators have noted the significant variability that exists in the resilience of different species to different pathogens, but species differences in injury and scarring is largely underinvestigated or often minimized. Yet, trauma and burn surgeons attest to the intrinsic variability of the inflammatory response after burn and traumatic injury in humans that are otherwise indistinguishable.[6](#wrr12422-bib-0006){ref-type="ref"} Interestingly, just as we noted the expression of human‐specific genes in human immune cells (Table [1](#wrr12422-tbl-0001){ref-type="table-wrap"}), Long and colleagues noted the wide and variable representation of primate‐ and human‐specific protein‐coding sequences in brain development.[3](#wrr12422-bib-0003){ref-type="ref"} We, therefore, considered the possibility that genes, originally selected to modulate human resilience to injury and infection, could have multifunctional biological effects, for example, when expressed in other tissues (Figure [1](#wrr12422-fig-0001){ref-type="fig"}). In one such example, CHRFAM7A[7](#wrr12422-bib-0007){ref-type="ref"} is a proinflammatory human‐specific gene that is a dominant negative inhibitor of the anti‐inflammatory α7‐nicotinic acetylcholine receptor (α7AChR) in peripheral tissues like macrophages. When expressed in the central nervous system, it presumably alters α7AChR activities on human cognition and memory. In other examples, the human antimicrobial defensins are highly multifunctional in different tissues[8](#wrr12422-bib-0008){ref-type="ref"} and the human‐specific TBC1D3 gene regulates human macropinocytosis and the formation of human microvesicles.[9](#wrr12422-bib-0009){ref-type="ref"}

![Injury, inflammation, and adaptation. New hominid behaviors, like the emergence of bipedal movement (trauma), harnessing of fire (burn injury) and the use of tools and weapons (injury/infection) is a positive selection for new genes. Positive adaptive selection enables new inflammatory activities (A) in response to new types of injuries. In this model, genes like CHRFAM7A, TBC1D3, and ARHGAP11B are initially selected in leukocytes and the in the human inflammatory response for their capacity to regulate ligand binding, internalization, and signaling, respectively. When these same genes are expressed in other tissues however (B), they can elicit new activities that also contribute to positive selection for example regulating neurotransmitter action (CHRFAM7A), cell--cell communication (TBC1D3) and progenitor cell growth (ARHGAP11B).](WRR-24-602-g001){#wrr12422-fig-0001}

So what are the consequences of an anthropogenic injury hypothesis to better understanding the mechanistic basis to human disease, and particularly wound repair and regeneration? First, like most genes, the expression of human‐specific genes in different tissues is highly contextual. Their multifunctional activities are dependent on where and when they are expressed (Figure [1](#wrr12422-fig-0001){ref-type="fig"}). In this proposed paradigm, a human‐specific gene in monocytes may have arisen to alter responsiveness after injury but may be retained in the human genome for unrelated activities, for example, in the central nervous system. Second, current experimental models of human disease do not test the contribution(s) of human‐specific genes to disease. To this end, the mouse still remains the most robust and experimentally tractable vertebrate animal model of human disease and it is possible to ask whether imparting mice with a human‐specific gene alters their injury response. Plasmids encoding human‐specific genes‐like ARHGAP11B have been injected into mice to generate a human phenotype.[10](#wrr12422-bib-0010){ref-type="ref"} Alternatively, human genes (e.g., CHRFAM7A) that encode antagonists (e.g., for CHRNA7) can be studied in mice to determine if over expression mimics the proinflammatory and behavioral phenotype of target gene knockout (e.g., CHRNA7). Finally, endogenous human‐specific genes in circulating and resident human immune cells can be studied in mice after the transplantation and engraftment of human hemato‐lymphoid immune systems.[11](#wrr12422-bib-0011){ref-type="ref"} With heterologous or autologous human skin grafts, it is even possible to create precision models of human diseases, including for wound repair and regeneration.

On a final note, the possibility that injury, inflammation, and infection responses contribute to the selection of species‐specific genes and regulatory pathways implies that they contribute factors to injury and wound healing responses in modern humans. If so, their study should be integrated into animal models of injury, wound healing and inflammation research. This is particularly relevant to "characteristically human" diseases like keloids and certain inflammatory bowel diseases that are difficult to model in animals and whose origins might trace to human behaviors like scarring and changes in the gut microbiome. Along this line, it is interesting to note that genomic expression data,[12](#wrr12422-bib-0012){ref-type="ref"} albeit controversial,[13](#wrr12422-bib-0013){ref-type="ref"}, [14](#wrr12422-bib-0014){ref-type="ref"}, [15](#wrr12422-bib-0015){ref-type="ref"} already points to the existence of characteristically human gene expression patterns in response to infection, trauma, and burn injury. We propose that while a better understanding of the contributions of species‐specific genes to the injury and inflammation response adds another level of complexity to biomedical research, it could lead to the identification of completely new drugs, new drug targets and the development of new therapeutics.
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